Sirtex Medical Europe GmbH

DER3201.HRB12781|Joseph-Schumpeter-Allee 33, 53227 BonnGermany|2003

Profit€1.2M

Revenue€19.5M

Balance€28.3M

About

Sirtex Medical Europe GmbH, headquartered in Bonn, is part of the group under parent company Grand Pharma Sphere Pte. Ltd. in Singapore and distributes SIR‑Spheres® Y‑90 resin microspheres to hospitals, university clinics and specialised distributors in Europe, the Middle East and Africa. The group's leading product, SIR‑Spheres® Y‑90 resin microspheres, is a prescription medical device for selective internal radio‑therapy (SIRT) to treat inoperable liver tumours. Since October 2023 the company also markets the embolic agent EmboCept® S DSM 50 μm for transarterial chemoembolisation; in 2024 a total of 3,382 doses were sold and German sales exceeded the prior year by more than 17%. On 7 September 2024 SIROS received approval in Germany and the first treatment was carried out on 30 September 2024.

Business purpose (commercial register)

Die Vertretung der Interessen der Sirtex Medical Ltd. und die Eröffnung von Geschäftsfeldern für die Sirtex Medical Ltd.

ClassificationWZ 2025

G.46.18.6 - Tätigkeiten der Großhandelsvermittlung von pharmazeutischen Erzeugnissen, medizinischen Artikeln, Krankenhaus-, Dental- und Altenpflegebedarf

Network

Levels

CompanyPersonShareholdingOfficer or Prokura

Products

Onkologie Therapie Therapeutika Software Medizinprodukte

Opportunities & Risks

Diversifizierung SIROS Wachstum Forschung Internationalisierung Weiterbildung

Inflation Geopolitische Risiken Regulatorische Anforderungen Rückerstattungsverwaltung Cyberangriff Materialkosten Energiekosten Personalmangel

This summary was generated with the help of AI. See our Data Quality Notice. Report error?

Source: German Commercial Register (Handelsregister) Bonn Local Court, HRB 12781 (as of 21 September 2026)

Company Structure

Shareholders

Name	Type	City
Michael Stelzer	Geschäftsführer(in)	Bad Honnef

Source: German Commercial Register (Handelsregister) Bonn Local Court, HRB 12781 (as of 21 September 2026)

Financials

Key financial figures over time — Sirtex Medical Europe GmbH
Year	Revenue	Profit	Balance	Employees
2024	€19,543,046	€1,218,964	€28,289,195	—
2023	€18,752,004	€1,172,709	€15,441,767	—
2022	€18,754,437	€1,027,779	€20,170,636	—
2021	€20,546,456	€2,782,806	€45,085,194	—
2020	€20,205,194	€1,550,704	€31,117,385	—
2019	€10,882,936	€0	€25,715,731	—
2018	€11,222,200	€0	€22,459,682	—
2017	€11,222,200	€0	€19,637,087	—
2016	Rohergebnis€18.9M²	€0	€19,637,087	—
2015	Rohergebnis€18.6M²	€0	€10,225,867	—

¹ Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.

² Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.

Source: German Company Register (Unternehmensregister)